ro6874281
mAbexperimentalADC
Clinical trial activity
6 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2015 (NCT02627274)
Timeline
Indications
Mechanism of action
- Interleukin-2 receptor beta chainINHIBITOR
IL2RB inhibitor
- IL-2R beta/gammaINHIBITOR
IL-2R beta/gamma inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- IL2
Oral
No
Parenteral
No
Topical
No
Also known as
- ro6874281
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03875079 | Phase 1 | May 24, 2019 | Roche |
| NCT03424005 | Phase 1/Phase 2 (Phase 2) | Mar 30, 2018 | Roche, Seattle Genetics |
| NCT03386721 | Phase 2 | Jan 25, 2018 | Roche |
| NCT03193190 | Phase 1/Phase 2 (Phase 2) | Jul 5, 2017 | Roche |
| NCT03063762 | Phase 1 | Mar 5, 2017 | Roche |
| NCT02627274 | Phase 1 | Dec 31, 2015 | Roche |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Roche | For profit | 6 | 6 | 2 | 2015 |
| Seattle Genetics | For profit | 1 | 0 | 1 | 2018 |
2 organizations
Page 1 / 1